Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,230.12
(
0.29%
)
US TECH 100
26,942.00
(
0.87%
)
Dow Jones
49,499.27
(
-0.31%
)
Brent Oil
107.18
(
0.06%
)
Bitcoin
78,503.95
(
-0.05%
)
News Focus
News Focus
Post# of 257484
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

vinmantoo

Send PM Follow Ignore
Followers 28
Posts 4698
Boards Moderated 0
Alias Born 07/25/2007

vinmantoo

Re: DewDiligence post# 243327

Friday, 07/29/2022 12:49:08 PM

Friday, July 29, 2022 12:49:08 PM

Post# of 257484

ENTA's EDP-235 is plainly more potent than Paxlovid. And without the manifold drug-drug interactions consequent to ritonavir, EDP-235 should be considerably safer than Paxlovid too.



I agree. Good news indeed. I have relaxed a bit now but obviously a ways to go before EDP-235 hits the finish line yet. I assume ENTA won't announce a partnership deal for EDP-235 before phase II is completed but I have been wrong before.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today